Spruce Street Capital LP
In its 13F for Q1 2026 (holdings as of March 31, 2026, filed May 14, 2026), Spruce Street Capital LP reported 28 stock positions worth $415.9 million. Its top holding was Relmada Therapeutics (RLMD) at 10.3% of the portfolio, followed by Kiniksa Pharmaceuticals Inte (KNSA, 8.8%) and LB Pharmaceuticals (LBRX, 8.1%). Compared with Q4 2025, it opened 7 new positions, sold out of 6, added to 12 and reduced 3. The biggest buy was Alto Neuroscience (ANRO, shares +495%) and the biggest sale an exit from Cidara Therapeutics (CDTX).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0002050194
- Portfolio Value
- $415.9M (Q1 2026)
- SEC Filing
- 0002050194-26-000004 ↗ filed May 14, 2026
Holdings Value
Holdings 28 stocks · $415.9M
| RLMD Relmada Therapeutics Inc. | 10.34% | 6,262,114 | $43.0M | Add +53.3% |
| KNSA Kiniksa Pharmaceuticals Inte | 8.81% | 761,063 | $36.6M | Add +75.0% |
| LBRX LB Pharmaceuticals Inc. | 8.09% | 1,376,159 | $33.6M | Add +36.9% |
| DNTH Dianthus Therapeutics Inc. | 7.53% | 373,274 | $31.3M | Add +25.5% |
| RLAY Relay Therapeutics Inc. | 7.14% | 2,984,125 | $29.7M | No change |
| ANRO Alto Neuroscience Inc. | 7.00% | 1,325,210 | $29.1M | Add +494.7% |
| CNTA Centessa Pharmaceuticals Ltd. | 4.68% | 489,849 | $19.5M | Add +528.0% |
| SVRA Savara Inc. | 4.44% | 3,383,175 | $18.5M | Add +40.3% |
| KALV Kalvista Pharmaceuticals Inc. | 4.34% | 897,681 | $18.1M | Add +131.4% |
| PCVX Vaxcyte Inc. | 3.43% | 245,709 | $14.3M | Reduce -38.6% |
| ELVN Enliven Therapeutics Inc. | 3.10% | 329,006 | $12.9M | Reduce -26.3% |
| SRZN Surrozen Inc. | 3.03% | 432,040 | $12.6M | No change |
| ENTA Enanta Pharmaceuticals Inc. | 2.83% | 932,598 | $11.8M | Add +139.3% |
| ALKS Alkermes PLC | 2.70% | 317,992 | $11.2M | New |
| CATX Perspective Therapeutics Inc. | 2.63% | 2,627,107 | $11.0M | New |
| NERV Minerva Neurosciences Inc. | 2.40% | 1,655,500 | $10.0M | No change |
| IPSC Century Therapeutics Inc. | 2.21% | 4,059,054 | $9.2M | Add +185.5% |
| ALMS Alumis Inc. | 2.08% | 392,574 | $8.6M | New |
| SABS Sab Biotherapeutics Inc. | 2.02% | 2,198,502 | $8.4M | No change |
| ERAS Erasca Inc. | 1.64% | 422,543 | $6.8M | Reduce -89.1% |
| IKT Inhibikase Therapeutics Inc. | 1.45% | 3,581,603 | $6.0M | No change |
| MAZE Maze Therapeutics Inc. | 1.44% | 200,000 | $6.0M | New |
| ANTX AN2 Therapeutics Inc. | 1.34% | 1,661,073 | $5.6M | New |
| LXEO Lexeo Therapeutics Inc. | 1.28% | 928,593 | $5.3M | Add +430.6% |
| HLXC Helix Acquisition Corp. Class A | 1.22% | 500,000 | $5.1M | New |
| ALEC Alector Inc. | 1.09% | 2,101,068 | $4.5M | Add +87.9% |
| LONA Leonabio Inc. | 0.92% | 393,701 | $3.8M | No change |
| CRVS Corvus Pharmaceuticals Inc. | 0.81% | 231,585 | $3.4M | New |
Portfolio Sells Q4 2025 → Q1 2026
| CDTX Cidara Therapeutics Inc. | Sold out | 0.00% | −16.95 |
| EYPT Eyepoint Inc. | Sold out | 0.00% | −5.93 |
| OCUL Ocular Therapeutix Inc. | Sold out | 0.00% | −3.14 |
| ERAS Erasca Inc. | Reduce -89.1% | 1.64% | −3.14 |
| PCVX Vaxcyte Inc. | Reduce -38.6% | 3.43% | −2.67 |
| ABVX Abivax SA-ADR | Sold out | 0.00% | −2.19 |
| HELP Cybin Inc. | Sold out | 0.00% | −2.08 |
| STRO Sutro Biopharma Inc. | Sold out | 0.00% | −0.29 |
| ELVN Enliven Therapeutics Inc. | Reduce -26.3% | 3.10% | +0.83 |
Portfolio Buys Q4 2025 → Q1 2026
| ANRO Alto Neuroscience Inc. | Add +494.7% | 7.00% | +5.69 |
| CNTA Centessa Pharmaceuticals Ltd. | Add +528.0% | 4.68% | +4.03 |
| RLMD Relmada Therapeutics Inc. | Add +53.3% | 10.34% | +3.82 |
| DNTH Dianthus Therapeutics Inc. | Add +25.5% | 7.53% | +3.48 |
| KNSA Kiniksa Pharmaceuticals Inte | Add +75.0% | 8.81% | +2.88 |
| ALKS Alkermes PLC | New | 2.70% | +2.70 |
| CATX Perspective Therapeutics Inc. | New | 2.63% | +2.63 |
| KALV Kalvista Pharmaceuticals Inc. | Add +131.4% | 4.34% | +2.27 |
| ALMS Alumis Inc. | New | 2.08% | +2.08 |
| IPSC Century Therapeutics Inc. | Add +185.5% | 2.21% | +1.74 |
| MAZE Maze Therapeutics Inc. | New | 1.44% | +1.44 |
| ANTX AN2 Therapeutics Inc. | New | 1.34% | +1.34 |
| HLXC Helix Acquisition Corp. Class A | New | 1.22% | +1.22 |
| CRVS Corvus Pharmaceuticals Inc. | New | 0.81% | +0.81 |
| ENTA Enanta Pharmaceuticals Inc. | Add +139.3% | 2.83% | +0.80 |
| LXEO Lexeo Therapeutics Inc. | Add +430.6% | 1.28% | +0.71 |
| LBRX LB Pharmaceuticals Inc. | Add +36.9% | 8.09% | +0.69 |
| ALEC Alector Inc. | Add +87.9% | 1.09% | +0.51 |
| SVRA Savara Inc. | Add +40.3% | 4.44% | −0.36 |